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Objective: The aim of the study was to evaluate biosynthetic absorbable
mesh in single-staged contaminated (Centers for Disease Control class II and
III) ventral hernia (CVH) repair over 24 months.
Background: CVH has an increased risk of postoperative infection. CVH
repair with synthetic or biologic meshes has reported chronic biomaterial
infections and high hernia recurrence rates.
Methods: Patients with a contaminated or clean-contaminated operative field
and a hernia defect at least 9 cm2 had a biosynthetic mesh (open, sublay,
retrorectus, or intraperitoneal) repair with fascial closure (n¼ 104). Endpoints
included overall Kaplan-Meier estimates for hernia recurrence and post-
operative wound infection rates at 24 months, and the EQ-5D and Short
Form 12 Health Survey (SF-12). Analyses were conducted on the intent-to-
treat population, and health outcome measures evaluated using paired t tests.
Results: Patients had a mean age of 58 years, body mass index of 28 kg/m2,
77% had contaminated wounds, and 84% completed 24-months follow-up.
Concomitant procedures included fistula takedown (n¼ 24) or removal of
infected previously placed mesh (n¼ 29). Hernia recurrence rate was 17%
(n¼ 16). At the time of CVH repair, intraperitoneal placement of the
biosynthetic mesh significantly increased the risk of recurrences
(P 0.04). Surgical site infections (19/104) led to higher risk of recurrence
(P< 0.01). Mean 24-month EQ-5D (index and visual analogue) and SF-12
physical component and mental scores improved from baseline (P< 0.05).
Conclusions: In this prospective longitudinal study, biosynthetic absorbable
mesh showed efficacy in terms of long-term recurrence and quality of life for
CVH repair patients and offers an alternative to biologic and permanent
synthetic meshes in these complex situations.
Keywords: abdominal wall reconstruction, bioabsorbable mesh, complex
ventral hernia repair, contaminated ventral hernia repair
(Ann Surg 2017;265:205–211)
P ermanent synthetic meshes have been used in clean wounds withlow infectious complications and excellent long-term results
with low recurrence rates.1–3 Synthetic meshes are nonabsorbable
meshes made of polypropylene (PP), expanded polytetrafluoroethy-
lene, polyester, lightweight PP, or a combination of these materials
used to obtain a ‘‘tension-free’’ closure in ventral hernia repairs.4
However, surgeons are reluctant to implant a permanent foreign
material in a patient undergoing a contaminated ventral hernia repair
because of the increased risk of postoperative infection, bowel
adhesion, mesh extrusion, mesh erosion, fistula formation, seroma
development, and pain.4–6 The most appropriate mesh for hernia
repair in clean-contaminated and contaminated wounds is not as
clear. Current options have included staged repairs, primary fascial
closure, or reinforcement with biologic mesh.7 The proposed
advantage of a biologic mesh is that the patient’s immune cells
can infiltrate the material to defend against the bacterial load and
eventually replace the biologic mesh with the host tissue.8 However,
the price of biologic grafts has caused an alarming increase in the cost
of complex abdominal reconstructions. Additionally, long-term dura-
bility of biologic grafts used for complex abdominal wall recon-
struction has been disappointing.7,9
Long-term absorbable synthetic materials, termed biosynthetic
meshes, have recently been introduced as a potential alternative to
biologic mesh for use during contaminated abdominal wall recon-
structions. Because of their breakdown via hydrolysis, biosynthetic
mesh may offer unique advantages when challenged with bacterial
colonization during complex abdominal wall reconstruction.10
The GORE BIO-A Tissue Reinforcement is a biosynthetic
mesh comprised of a bioabsorbable polyglycolide—trimethylene
carbonate copolymer, which is gradually absorbed by the body.
The open 3-dimensional (3D) matrix structure, with highly inter-
connected pores, facilitates tissue generation and healing. Degra-
dation occurs via a combination of hydrolytic and enzymatic
pathways. In vivo studies with this copolymer indicate that the
bioabsorption process should be complete within 6 to 7 months.11
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The Complex Open Bioabsorbable Reconstruction of the
Abdominal Wall (COBRA) study prospectively evaluated the use
and performance of GORE BIO-A Tissue Reinforcement, a biosyn-
thetic mesh, for reinforcement of the midline fascial closure in the
single-staged repair of contaminated ventral hernias.
METHODS
Study Design
This prospective, multicenter, observational study conducted
in 9 centers across the United States and the Netherlands, between
February 2011 and December 2014, was approved by the Institu-
tional Review Board of all sites. The study is registered on www.cli-
nicaltrials.gov # NCT01325792. Informed consent to participate in
this study was provided by all patients enrolled. Adult patients with
incisional hernias of at least 9 cm2 by physical examination, under-
going a planned single-staged repair of a ventral/incisional hernia
with an operation classified by Centers for Disease Control (CDC)
wound criteria as a clean-contaminated or contaminated wound,12
were eligible for study enrollment. Patients were enrolled if a single
unit of biosynthetic mesh (GORE BIO-A Tissue Reinforcement;
Flagstaff, Arizona) could adequately reinforce the midline fascial
closure with at least 4 cm of lateral overlap.
Patients were excluded from the study if they had a clean
(CDC class I) or dirty (CDC class IV) wound, had a laparoscopic
repair, pre-existing systemic infection at the time of repair, cirrhosis,
renal failure on dialysis, immunocompromised (chronic immuno-
suppression therapy [prednisone >10mg/d], solid organ transplant
patient, or actively on chemotherapy), diagnosed collagen formation
disorder, and a body mass index (BMI) >40 kg/m2. Patients who
required more than 1 mesh to be quilted together or could not achieve
midline fascial closure without excessive tension or requiring
planned, multistage repair were excluded.
Surgical Technique
Surgical repair of the hernia required appropriate bioburden
reduction technique with debridement of all nonviable tissue,
removal of infected, nonincorporated prosthetic materials (both
synthetic and biologic), and reconstruction of the gastrointestinal
(GI) tract when appropriate. Defects were measured intraoperatively
with a ruler and documented as maximal vertical (cm) and horizontal
(cm) dimensions in accordance with the European Hernia Society
guidelines.13 As per study protocol, the biosynthetic mesh was placed
as a sublay in either the intraperitoneal or retrorectus position, based
on the discretion of the surgeon, to reinforce midline fascial closure.
For both intraperitoneal and retrorectus placement, the interrupted,
transfascial sutures were placed at least 4 cm from the medial edge of
the rectus abdominis muscles bilaterally to secure the biosynthetic
mesh so that it spanned the entire midline closure. With either
placement, the primary fascia was re-approximated. Surgeons were
permitted to performmyofascial releases as deemed necessary, based
on the size of the defect, and the resultant tension on the fascial
closure. For the purposes of analysis, a component separation was
defined as those patients who had an incision in one of the lateral
abdominal wall muscles (transversus abdominus or external oblique
muscle). An anterior component separation was performed when
external oblique muscles were released. A posterior component
separation was defined as those patients undergoing incisions in
both the posterior rectus sheath and the transversus abdominus
muscle. If only the posterior rectus sheath was incised and the
dissection was extended to the linea semilunaris and the posterior
rectus sheaths were re-approximated to allow the mesh to be placed
in retrorectus space as described by Stoppa,14 it was not considered a
component separation. Anterior rectus sheath incisions that involved
simply incising the anterior rectus sheath to provide fascial advance-
ment (not a turnover procedure) were not recommended, but did not
constitute a protocol deviation. The exact myofascial releases per-
formed, the location of the mesh, number and placement of drains,
and the duration of drains were recorded and managed at the
discretion of the surgeon’s standard management protocols. The
biosynthetic meshes were secured in place with PDS (Ethicon,
New Jersey) or MAXON (Covidien, CT) suture using interrupted
transfascial sutures. Antibiotics were continued for the first 24 hours
according to Surgical Care Improvement Project (SCIP) protocols.
Recurrence and complication rates were evaluated by the treating
surgeon at 30 days, 6, 12, and 24 months review.
Endpoints
The primary endpoint was the rate of hernia recurrence,
determined by physical examination, at 2 years. Hernia recurrences
were recorded if there was a new hernia within 7 cm of the repair, and
recurrences were categorized as midline, at the stoma site, or both.3
Patients who had their intact midline repair violated during the 2-year
follow-up period for reasons not related to the index hernia repair
were excluded from the final recurrence analysis. For analysis
purposes, if the prosthetic material came in contact with a stoma
site in patients with a concomitant stoma with or without a para-
stomal hernia component, it was considered part of the primary
repair. Recurrence was evaluated postoperatively at 30 days, 6, 12,
and 24 months.
Secondary endpoints included incidence of wound events and
quality-of-life assessments. Wound events were classified as surgical
site infections based on CDC criteria into superficial, deep, or organ
space.12 Surgical site occurrences were reported based on the Ventral
Hernia Working Group definitions.6,15 Interventions for wound
events were categorized as: antibiotics only, bedside wound inter-
ventions, percutaneous interventions, or surgical debridement. If
surgical debridement was required, prosthetic management was
defined as: no intervention, partial resection, or full removal of
the biosynthetic mesh.
Quality of life and return of function were measured using the
Short Form 12 Health Survey, version 2 (SF-12) and the EQ-5D at
baseline, and postoperative day 30 and at 6, 12, and 24 months. The
SF-12 measures generic health concepts across age, disease, and
treatment groups.16 The instrument measures health from the
patients’ point of view by scoring standardized response to standard
questions. Eight concepts commonly represented in health surveys
are assessed: physical functioning, role functioning physical, bodily
pain, general health, vitality, social functioning, role functioning
emotional, and mental health. The results of test items scored were
normalized and expressed in terms of 2 meta-scores: the Physical
Component Summary (PCS) and the Mental Component Summary
(MCS). A higher SF-12 score indicates better physical functioning.
The EQ-5D Health Questionnaire—a standardized measure of
health status and treatment—consists of 2 scores: the EQ-5D descrip-
tive system and the EQ visual analog scale (EQ-VAS).17 The EQ-5D
descriptive system is comprised of 5 dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety-depression) and 3
levels (no problems, some problems, and extreme problems). Patients
completed the questionnaire based on how good or bad their health
was for that day of administration relative to their ventral hernia
repair from which a single-digit score described the patients’ health
state. The EQ-VAS is patient-rated assessment of health on a vertical,
visual analog scale on a spectrum of ‘‘best imaginable health state’’
and ‘‘worst imaginable health state,’’ and is quantified as a measure
of health outcome as judged by the individual respondents.
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Follow-up
Patients were followed prospectively from the time of surgical
repair of their hernia to study completion. All patients were included
in long-term quality-of-life analysis regardless of the presence of
recurrence, reoperation, or other events. Patient assessments were
completed preoperatively (within 30 days of surgery), and post-
operatively on day 30 (2 weeks), and at 6 months, and 1 and 2 years
(1 month).
Statistical Analysis
The power of the study was based on a 0.05, an estimate of the
39% recurrence rate of patients with biosynthetic mesh, and an
expected rate of 20% loss to follow-up, thus requiring a sample size
of 100 patients. The calculation assumed a 50% recurrence rate for
those patients undergoing component separation alone in complex
ventral hernia repairs, which is in line with that reported in the
literature.18
All analyses were conducted on the intent-to-treat (ITT)
population. Overall recurrence and infection rates were estimated
using Kaplan-Meier estimation and log-log 95% confidence intervals
(CIs). Numerical variables were summarized using means, medians,
standard deviations, quartiles, and 95% CI. Categorical variables
were summarized using counts and percentages. Statistical differ-
ences for the SF-12 and EQ-5D over time were evaluated using
paired t tests, using P< 0.05 as the cut-off for statistical significance.
Post hoc evaluations of differences between subgroups were
evaluated using Fisher exact tests (for 2 category variables), chi-
square tests (for 3 category variables), t tests (for numerical
variables predefined as normally distributed), Wilcoxon rank-sum
tests (for numerical variables predefined as non-normally distrib-
uted), log-rank tests (for evaluating Kaplan-Meier estimates of events
over time), andWald tests with Efron ties (for evaluating Cox models
of events over time). Statistical analysis was done using SAS
Software (Cary, NC), version 9.2.
RESULTS
A total of 104 patients had hernia repair with a single sheet of
biosynthetic mesh, of which 87 (84%) completed the 24-month
follow-up period (Supplemental Digital Content Fig. 1 http://links.
lww.com/SLA/A958). Patient characteristics, comorbid conditions,
and wound and hernia defect characteristics at the time of ventral
hernia repair are presented in Table 1. Patients had a mean age of 58
years, the majority were women (60%), more than a third were obese
(BMI > 30 kg/m2) and had a prior wound infection, and 45% had
recurrent incisional hernias present (Table 1). Of the surgical wound
CDC classifications, 77% were contaminated and 23% were clean-
contaminated. A stoma was present in 48% of patients and 21% had a
concomitant parastomal hernia repair at the time of midline hernia
repair. For the purposes of analysis, a parastomal hernia that the
stomawas taken down and moved to another location was considered
class III. If the stomawas left in situ and not moved, it was considered
a class II. Other reasons for a contaminated wound included repair of
a gastrointestinal (GI) fistula, or nonhealing abdominal wound.
Concomitant procedures performed during abdominal wall recon-
struction included GI reconstruction (bowel resection, enterocuta-
neous fistula repair, ostomy reversal, and ostomy creation),
cholecystectomy, urinary and gynecologic resections, and removal
of actively infected mesh. Of the 104 patients who underwent repair
of a midline hernia, 22 patients required a concomitant repair of both
a midline and parastomal hernia. The mean size and width of hernia
defects was 137 cm2 and 9 cm (Table 1).
Primary fascial closure with a single unit of biosynthetic mesh
was achieved in all patients. A concomitant component separation
was performed in 68 patients, which included external oblique
release (n¼ 21) and transversus abdominus release (n¼ 50)
(Table 2). Thirty patients had a posterior rectus sheath incision alone
with retromuscular mesh placement as described by Stoppa.14 Three
patients had an anterior rectus sheath incision.
The placement of the biosynthetic mesh was left to the
discretion of the surgeon and a clear trend emerged for placement
of the mesh in the retrorectus position. Only 10% of the biosynthetic
meshes were placed in the intraperitoneal position. The mean
operative time was 244 minutes and median length of hospital stay
was 7 days. Extended hospitalization was required for 1 patient with
acute respiratory distress syndrome requiring prolonged intubation.
Drains placed in the retrorectus space in contact with the mesh were
TABLE 1. Patient Demographics, Comorbid Conditions, and
Wound and Hernia Defect Characteristics
n¼ 104
Preoperative variables (mean)
Age, y (range) 58 (27–91)
Sex (female), n (%) 62 (60)
Body mass index, kg/m2 (range) 28 (17–40)
Recurrent hernia repaired, n (%) 47 (45)
Comorbid conditions, n (%)
Previous abdominal wall infection 36 (35)
Obesity 35 (34)
Inflammatory bowel disease 27 (26)
Active smoking 20 (19)
Diabetes mellitus 19 (18)
Chronic obstructive pulmonary disease 11 (11)
Perioperative variables
Contamination, n (%)
Clean-contaminated wound (CDC class II) 24 (23)
Contaminated wound (CDC class III) 80 (77)
Reasons for contamination, n (%)
Presence of a stoma 50 (48)
Bowel resection 32 (31)
Infected mesh removal 29 (28)
Repair of gastrointestinal fistula 24 (23)
Nonhealing abdominal wound 24 (23)
Ostomy reversal 23 (22)
Parastomal hernia repair 22 (21)
Urologic and gynecologic procedure 8 (8)
Diverting ostomy procedure 7 (7)
Cholecystectomy 6 (6)
Hernia defect characteristics, mean (range)
Defect size, cm2 137 (10–513)
Defect width, cm 9 (3–25)
Patients may have had more than one reason for contamination.
CDC indicates Centers for Disease Control and Prevention.
TABLE 2. Operative Characteristics
Variables
Intent-to-treat
Population (n¼ 104)
Mean operating time, min (range) 244 (60–505)
Component separation, n (%) 68 (65)
Posterior component separation 50 (48)
Anterior component separation 21 (20)
Placement of biosynthetic mesh
Retrorectus location, n (%) 94 (90)
Intraperitoneal location, n (%) 10 (10)
Median hospital stay, d (range) 7 (3–92)
Mean days to drain removal, d (range) 12 (2–33)
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removed an average of 12 days after surgery (Table 2). Five deaths
occurred during the study, of which 4 succumbed to cancer (glio-
blastoma, GI stromal tumor, lung cancer, and metastatic cancer) and
1 had a history of cancer from an unknown site. Five patients had
another operation during the study period in which their midline
repair was disrupted for reasons of complications related to Crohn
disease, removal of previously placed biologic and permanent syn-
thetic mesh that had been left at index operation and was infected,
anastomotic leak, and leaking ileostomy site.
Hernia Recurrence
The Kaplan-Meier analysis overall hernia recurrence rate
in the ITT population (n¼ 104) was 17% (n¼ 16 patients) at the
24-month follow-up period (Fig. 1). The 16 recurrences included
occurrence at the midline hernia (n¼ 13) and 3 parastomal sites
(n¼ 3). When estimating only midline hernia recurrence, the
Kaplan-Meier recurrence rate at 24 months was 14%. The recurrence
rate was higher in patients with mesh placement in the intraperitoneal
position (40%; 4/10) versus those with placement in the retrorectus
position (13% [12/94]; P¼ 0.0451). Cox hazard ratio (HR) analysis
for predictive baseline risk factors revealed increased risks for hernia
recurrence for intraperitoneal mesh placement (HR¼ 3.41 [95% CI,
1.098–10.590]; P¼ 0.0339) compared with retrorectus placement.
Time to hernia recurrence was shorter for patients with postoperative
infection than those patients without (P¼ 0.0098) (Supplemental
Digital Content Fig. 2 http://links.lww.com/SLA/A958) and with
parastomal compared with midline hernia recurrences (P< 0.0001)
(Supplemental Digital Content Fig. 3 http://links.lww.com/SLA/
A958). Significant baseline risk factors for hernia recurrence are
shown in Table 3.
Postoperative Wound Events
A postoperative wound event developed in 29 patients. The 21
surgical site infection events that occurred in 19 patients were
categorized by the CDC criteria (Table 4). In all cases, superficial
surgical site infections (n¼ 9) resolved with oral or intravenous
antibiotics. Deep surgical site infections (n¼ 10) required percuta-
neous drainage alone (n¼ 6), minor operative debridement (n¼ 3),
and widewound debridement with partial mesh excision (n¼ 1). Two
organ space infections occurred in patients with a leak from a GI
anastomosis in the early postoperative period and were unrelated to
the biosynthetic mesh. No cases required complete explantation of
the biosynthetic mesh. All wounds were completely healed at long-
term follow-up. Other wound events included development of a
postoperative seroma (n¼ 6), which resolved spontaneously
(n¼ 3) or required percutaneous drainage and eventually resolved
(n¼ 3). Two recurrent enterocutaneous fistulas developed in patients
undergoing takedown of an enterocutaneous fistula and were felt to
be unrelated to the biosynthetic mesh. Two postoperative bowel
obstructions occurred in patients with mesh placed in the retrorectus
position. One occurred during the primary hernia repair and resolved
after re-exploration and revision of the anastomosis. The second
occurred 212 days after hernia repair and was resolved with complete
adhesiolysis of the GI tract.
Post hoc analysis for predictive baseline or operative risk
factors for postoperative infections were significant (all P 0.05) for
diabetes mellitus (HR¼ 2.969; 95% CI, 1.169–7.544), GI fistula
takedown (HR¼ 4.486; 95% CI, 1.820–11.058), and mesh present
from prior repair (HR¼ 2.666; 95% CI, 1.049–6.775). The only
significant predictor of deep surgical site infection was the presence
of a GI fistula (HR¼ 5.605 [95% CI, 1.581–19.874]; P¼ 0‘.0076)
during ventral hernia repair.
FIGURE 1. Kaplan-Meier estimate of freedom from postoper-
ative hernia recurrence: all participants (n remaining at
risk¼85 and 74 patients at 12 and 24 months, respectively).
TABLE 3. Recurrence and Risk Baseline Factors for Postoperative Hernia Recurrence
Variables
Intent-to-treat Population (n¼ 104)
Hernia Recurrence, n (%)
16 (15.4)
Risk Baseline Factors
Patients With Hernia
Recurrence (n¼ 16)
Patients Without Hernia
Recurrence (n¼ 88) P
BMI (kg/m2), mean (range) 30 (22–39) 27 (17–40) 0.046
Defect length (cm), mean (range) 11 (5–20) 15 (3–27) 0.044
Postoperative superficial incisional wound infection, n (%) 5 (31%) 4 (5%) 0.004
TABLE 4. Postoperative Wound Events and Surgical Site
Infections
Variables n¼ 104
Wound events, n (%) 33 (28)
Surgical site infectiony 21 (18)
Seroma 6 (6)
Fistula 2 (2)
Bowel obstruction 2 (2)
Wound dehiscence 1 (1)
Hematoma 1 (1)
Postoperative infectionsy, n (%) 21 (18)
Superficial incisional infections 9 (9)
Deep incisional infections 10 (10)
Organ space infections 2 (2)
Patients may have had more than one wound event.
yCategorized by CDC criteria; 21 infections occurred in 19 patients.
CDC indicates Centers for Disease Control.
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Patient-reported and Quality-of-life Outcomes
Patients reported overall sustained improvement in health over
the 2-year follow-up period as measured by the EQ-5D Index, EQ
VAS, and SF-12 scores (Table 5, Supplemental Table 1 http://links.
lww.com/SLA/A958). The increase from baseline on the EQ-5D
Index, EQ VAS, and the SF-12 Physical scores was significant
(P< 0.05) at 6 months postoperatively, and improvement was sus-
tained at the 12 and 24-month (P< 0.05) follow-up time points
(Supplemental Digital Content Figs. 4, 5, and Fig 6 http://links.
lww.com/SLA/A958). Patients without stomas versus with stomas at
baseline or with an infected mesh removed versus not at the time of
surgery reported significantly greater improvement on the SF-12
physical score (P< 0.05). Stratification of the SF-12 physical score
by hernia recurrence, or infections during study, did not reveal
significant differences (Fig. 2). The increase from baseline for the
SF-12 Mental score was significant at 12 and 24 months (P< 0.05)
(Supplemental Digital Content Fig. 7 http://links.lww.com/SLA/
A958).
DISCUSSION
This prospective COBRA study demonstrated that the bio-
synthetic mesh, GORE BIO-A Tissue Reinforcement, performed
well in the reinforcement of the midline fascial closure in the
single-staged repair of contaminated ventral hernias. Overall, hernia
recurrence occurred in 16 patients with a Kaplan-Meier recurrence
rate of 17% at 24 months.
Prospective, longitudinal, or randomized clinical studies eval-
uating outcomes for ventral hernia repair utilizing biologic mesh in
clean, clean-contaminated, contaminated, or infected wounds are
deficient. In fact, the Repair of Infected and Contaminated Hernias
(RICH) trial is the only long-term, multicentered, prospective trial to
evaluate biologic mesh in CDC class II to IV wounds.9 The RICH
trial reported 66% surgical site occurrence and 28% hernia recur-
rence (ITT) after 2 years follow-up in patients who underwent ventral
hernia repair with a noncross-linked porcine dermis. Hernia recur-
rence rate based on clinical assessment was 19% at 1 year and 28% at
2 years. The most provocative outcome was that operative technique
had a significant influence on recurrence. Despite the use of myo-
fascial release as described by Ramirez (anterior component separ-
ation release), facial closure was not completed in 19% of the repairs.
The recurrence rate in ‘‘bridged’’ ventral hernia repairs was 45%. In
addition, location of mesh placement seemed to influence recurrence
rates in a similar fashion to the COBRA study, with a higher rate of
recurrence when the biologic mesh was placed intraperitoneally as
compared with a retrorectus position.19 The primary endpoint in the
COBRA study was ventral hernia recurrence. Based on Kaplan-
Meier analysis, the overall hernia recurrence rate was 17% at 24
months—almost 11% less than in the RICH trial. Similar to the RICH
trial, hernias repaired with intraperitoneal mesh placement in the
COBRA study had a higher recurrence rate (3.41-fold increase). The
overall reduction is likely due to technique as all patients in the
COBRA study had primary fascial closure and 90% had retrorectus
placement. In a nationwide prospective study of outcomes after
elective incisional hernia repair, intraperitoneal placement of syn-
thetic mesh had a cumulative reoperation rate for recurrence that was
significantly greater than onlay or sublay (retrorectus) mesh place-
ment.20 Expertise is required to perform retrorectus or preperitoneal
dissection and perforator sparing anterior component separation
release or transversus abdominus/posterior component separation
release. This may limit more universal application of advanced
ventral hernia repair techniques that ultimately improve patient
outcomes. Another randomized study using component separation
technique to repair clean (CDC class I) or clean-contaminated (CDC
class II) ventral hernias reported 53% of patients had development of
a major wound complication postoperatively and hernia recurrence at
36 months.18 A meta-analysis of the randomized study in addition to
small retrospective studies with component separation used to repair
large abdominal wall defects reported 24% morbidity rate and at 1
year and the hernia recurrence rate of 18%. Most of the repairs
reported from these studies did not include use of a synthetic,
biologic, or biosynthetic mesh.18,21
Achieving value, outcomes important to patients at a cost the
healthcare market is willing to pay, has become an imperative in our
unsustainable model of volume-based reimbursement for healthcare
delivery. Biologic mesh has increased the cost of ventral hernia repair
significantly. A recent study at the University of Kentucky reported
that the median contribution margin for ‘‘complicated’’ open ventral
hernia repairs (CPT codes 49560, 49561, 49565, and 49566) utilizing
biologic mesh was $4560, and the median net financial loss was
TABLE 5. Patient-reported Outcomes (Change in Scores From Baseline Over 24 Months)
Variable, Mean Baseline Mean Change
Variable, Mean Month 1 Month 6 Month 12 Month 24
EQ-5D Index 0.73 –0.02 0.10 0.10 0.11
EQ-5D VAS 63.9 –0.7 9.0 8.4 10.1
SF-12 Physical 38.6 –3.9 4.5 6.2 4.9
SF-12 Mental 42.2 0.6 1.7 3.3 3.7
P< 0.05.
SF-12 indicates Short Form 12 Health Survey; VAS, visual analog scale.
FIGURE 2. Change in SF-12 physical score from baseline
stratified by hernia recurrence during study (n¼10 for patients
with hernia recurrence evaluated at 12 and 24 months; n¼55
and 49 for patients without hernia recurrence evaluated at 12
and 24 months, respectively). SF-12 indicates Short Form 12
Health Survey.
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$8370.22 Recurrence rates have a tremendous financial impact on
healthcare expenditures. It was estimated by Poulose et al23 that a 1%
reduction in hernia recurrence would result in at least a US $32
million yearly savings in procedural costs. These studies highlight
the need for more cost-effective alternatives to biologic mesh for
ventral hernia repair. Outcomes evaluating large-pore, reduced-
weight synthetic mesh in clean-contaminated and contaminated
ventral hernia repairs have been published. Carbonell et al24 reported
primary outcomes of surgical site infection, surgical site occurrence,
need for mesh removal, and hernia recurrence in 100 patients with
CDC class II to III wounds undergoing ventral hernia repair with
retrorectus mesh placement. The overall incidence of surgical site
occurrence was 31%, higher in the contaminated than in the clean-
contaminated cases. The 30-day surgical site infection rate was 14%.
Their recurrence rate was 7% (ITT) at mean follow-up of 10.8 9.9
months (range 1–63 mo). Mesh removal was required in 4 patients.
The authors hypothesized that the overall cost for the 100 pieces of
30 30 cm large-pore, reduced-weight synthetic mesh at 15 cents/
cm2 to repair the ventral hernias, was equivalent to the cost of one
single piece of biologic mesh ($10,000). Despite the significant
potential for reduction in healthcare expenditures with the use of
synthetic mesh in these patients, it is off-label to use synthetic mesh
in clean-contaminated, contaminated, or infected wounds. As such,
the surgical community is reluctant to do so until high-level clinical
outcomes data are available. Furthermore, large-pore, reduced-
weight mesh does have its limitations. Petro et al25 described 7
patients with central mesh failure after ventral hernia repair with
lightweight monofilament polyester mesh placed in the retrorectus
position with complete posterior and anterior fascial coverage. In
clean or CDC class I wounds, a prospective randomized trial
demonstrated a trend (P¼ 0.052) toward an increased recurrence
rate for large-pore, lightweight mesh (17%) compared with ‘‘stand-
ard’’ mesh (7%) for retrorectus ventral hernia repairs.26
An alternative to biologic mesh for the repair or clean-con-
taminated and contaminated ventral hernia repairs is absorbable
synthetic mesh. Constructive remodeling, a balance between scaffold
degradation and collagen deposition with biomechanical integrity
and resistance without evidence of biomaterial ‘‘footprint’’ long-
term, is a potential benefit of absorbable materials, whether biologic
or synthetic. Absorbable synthetic mesh has the prospective advan-
tages of a reduced cost, minimal constraints in manufacturing
alternative sizes (lengths, widths, and thicknesses), informed consent
in certain religious or cultural groups, and ability to be iterative in
generational improvements in mesh constructs based on outcome
studies compared allogeneic or xenogeneic mesh. The absorption
profile of the synthetic mesh, degradation versus time, may alter
‘‘constructive remodeling,’’ but comparative biomechanical data are
not available.
In the past, surgical studies strictly assessed clinical outcomes
without recognizing the impact of disease, convalescence from
treatment, and resolution of symptoms have on patients. During
the past decade, many have recognized this important aspect of
surgical treatment necessitated recording and reporting. As a result, a
greater focus has been made on assessing quality of life surrounding
surgical procedures. Some groups have gathered significant data and
have successfully generated quality-of-life assessment tools specific
to a surgical procedure or a disease process. Although beneficial,
these disease-specific instruments limit the ability to compare results
from one event (eg, a hernia repair) to another, thereby impacting
generalizability of the results.
This study utilized general quality-of-life assessment tool—
the SF-12—and it introduced the EQ-5D and EQ-5D VAS in the
hernia repair literature. Both instruments demonstrated sustained
improvement in physical health, from the preoperative to 6-month
postoperative time points onto the 24-month time point. Not
surprisingly, assessment of physical health at 1 month after surgery
showed an initial drop as patients still contended with postoper-
ative discomfort. However, the results seen in the SF-12 mental
health domain suggested a more complex impact of hernia repair
on these patients. For example, participants in the study group
underwent both hernia repair and another procedure that included
addressing an ongoing active infection or a procedure that fre-
quently involved an intestinal procedure. One may hypothesize,
these patients remained cautiously optimistic initially after
surgery. However, they were reluctant to truly feel at ease well
past the repair, having experienced problems after previous oper-
ations. Conditioning from previous bad experience, even if after
only one such event, has permanently limited their ability to
approach convalescence positively.
Considering this side effect of previous experience, one must
recognize the limitations of outcomes research in patients with
complex ventral hernia repair. The definition of a successful outcome
is not clear. Whereas the surgeon often measures success by the
absence of recurrence, patients often do not interpret their outcomes
in a similar fashion. For example, a patient with a large recurrent
defect, an enterocutaneous fistula, and an infected mesh with daily
foul-smelling drainage likely, has a completely different outlook on
their repair and the measure of success. For this patient, the resol-
ution of the infection and reconstruction of the GI tract is the most
important measure of success, and a small asymptomatic recurrence
at 24 months is of little consequence.
This study is not without limitations. First, the selected study
format of a longitudinal observation of a patient cohort potentially
limits the ability to apply these results. Lack of a control group or any
element of randomization does introduce an opportunity to suggest
that alternative mesh options, including a biologic product, could
provide a similar outcome. Second, the duration of follow-up of 24
months is a commonly selected time point, but it is well understood
that the longer hernia repair patients are followed, the greater the rate
of recurrence. However, the product used in this study undergoes
hydrolysis, as it is replaced with vascularized soft tissue. This process
is generally considered to have completed by 6 to 7 months. There-
fore, the 24-month window seems to provide a more than adequate
time period for recurrence to develop. Third, the diversity of hernia
size may represent a challenge to draw conclusions. Inclusion criteria
allowed hernias as small as 9 cm2. However, the mean defect size was
137 cm2, with a range from 10 to 513 cm2. So, the majority of hernias
were well in excess of this minimum. Fourth, the clinical charac-
teristics of patients varied within the study group, with several
patients undergoing straightforward, clean-contaminated cases sim-
ultaneous to hernia repair, whereas others underwent contaminated
cases that addressed infected mesh removal. Arguably, this could
have also been approached with separated cohorts. Fifth, there are
still inherent limitations of outcomes research (eg, quality-of-life
indices) in patients with complex ventral hernia repair. The definition
of a successful outcome is not as clear as would be desired. Sixth,
physical examination, although an appropriate standard for assess-
ment, is not as accurate as a computerized tomogram (CT). Routine
postoperative CT examination of the abdominal wall would have
been more accurate. However, this approach to hernia assessment has
proven controversial as well. In some studies, the CT findings were
not associated with sign or symptoms of a hernia. The clinical
relevance of this scenario is not clear and in fact raises more
questions than not. Therefore, relying on clinical evaluation with
questioning and physical examination is more appropriate. Finally,
the generalizability of any multicenter prospective trial or for that
matter randomized controlled trial is always subject to real-time data
and experience.
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In conclusion, despite a longitudinal cohort format, the impact
of this study should not be underestimated. This prospective study
demonstrated that the biosynthetic mesh for reinforcement of the
midline fascial closure in the single-staged repair of contaminated
ventral hernias had low hernia recurrence and postoperative wound
infection rates, particularly in light of a patient population with CDC
class II and III wounds. The use of a biosynthetic alternative to
biologic mesh provides a clear opportunity for reducing costs in
caring for these complex patients.
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